{
    "nct_id": "NCT04959981",
    "official_title": "A Phase 1b Master Protocol of Agents Targeting the Mitogen-Activated Protein Kinase Pathway in Patients With Advanced Non-Small-Cell Lung Cancer",
    "inclusion_criteria": "* Age ≥ 18 years.\n* Willing and able to give written informed consent.\n* Have histologically or cytologically confirmed NSCLC, with presence of EGFR mutation(s) sensitive to EGFR inhibitors, or KRAS G12C mutation.\n* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.\n* Adequate bone marrow and organ function.\n* Have ECOG performance status of 0 or 1.\n* Willing to comply with all protocol-required visits, assessments, and procedures.\n* Able to swallow oral medication.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 99 Years",
    "exclusion_criteria": "* Concurrent treatment with any systemic anticancer therapy for NSCLC, including any approved or investigational agent.\n* For participants with EGFRm NSCLC: prior therapy with a RAS, RAF, MEK, or ERK inhibitor.\n* For participants with KRAS G12Cm NSCLC: prior therapy with a SHP2, ERK, or KRAS G12C inhibitor (depending on which cohort is being considered for enrollment).\n* Palliative radiotherapy within 7 days of enrollment.\n* History of unacceptable toxicity to treatment with osimertinib or sotorasib.\n* Major surgery within the 28 days of enrollment.\n* Unresolved toxicities from prior systemic therapy greater than NCI CTCAE grade 1 at time of enrollment, except for toxicities not considered a safety risk (eg, alopecia, vitiligo, and grade 2 neuropathy due to prior chemotherapy).\n* History of another malignancy ≤5 years prior to first dose, except for patients who are disease-free for >2 years after treatment with curative intent or who have carcinoma in situ.\n* Symptomatic and unstable brain metastases, or spinal cord compression, except for patients who have completed definitive therapy (surgery or radiotherapy), are not on steroids, and have a stable neurologic status for a least 2 weeks after completion of the definitive therapy and steroids.\n* History of or clinically active ILD, drug induced ILD, or radiation pneumonitis that required steroid treatment.\n* Impaired cardiovascular function or clinically significant cardiovascular disease.\n* History or current evidence of retinal pigment epithelial detachment (RPED), central serous retinopathy, retinal vein occlusion (RVO), or predisposing factors to RPED or RVO.\n* Any evidence of severe or uncontrolled systemic disease or evidence of any other significant clinical disorder or laboratory finding that renders the patient inappropriate to participate in the study.\n* Pregnant or breastfeeding women.\n* Contraindication to osimertinib or sotorasib use as per local label.",
    "miscellaneous_criteria": ""
}